What Panion & BF Biotech Inc. does

Panion & BF Biotech Inc. (寶齡富錦生技, TWSE: 1760) is a Taiwan-headquartered, publicly listed biotech pharmaceutical company founded in 1976 that operates across four horizontal business segments: disease treatment (Nephoxil, its flagship ferric citrate-based kidney drug for hyperphosphatemia and iron deficiency anemia in dialysis and CKD patients, plus generic pharmaceuticals across cardiovascular, anti-infective, dermatology, and other therapeutic categories), disease prevention (disinfectants, antibacterial wipes, antiseptic solutions), disease diagnosis (Vstrip brand rapid diagnostic tests for H. pylori, influenza A+B, and Group A Streptococcus), and delay-of-aging (BDS, THE ONE, Germain, Spring, Neo Living, Reverse Age cosmeceutical brands and sports medicine under the RaceOn sub-brand). The company's proprietary technology platforms include Sachitin, a 20+ year-developed chitin-polysaccharide chelate derived from purified Ganoderma lucidum cell walls validated through a five-stage pharmaceutical research protocol, and BiD250 Smart Deep Skin Technology, a 40+ year-controlled-release delivery system that targets the approximately 250μm epidermal layer for enhanced active-ingredient absorption in cosmeceuticals.

PBF manufactures at two PIC/S GMP-certified facilities in Taoyuan (Pingzhen and Dayuan) and is described in the data as the only Taiwanese pharmaceutical company holding both PIC/S GMP pharmaceutical certification and cosmetic GMP certification. The company's revenue model combines (a) one-time product sales across pharmaceutical, cosmeceutical, diagnostic, and consumer-health categories, (b) licensing royalties from Nephoxil distributed through regional partners including Akebia (US), JT/Torii (Japan), Averoa (EU), DKSH (Thailand), Zuellig Pharma (Taiwan), and Weigao Group (China), and (c) direct-to-consumer e-commerce through its own storefronts for BDS and THE ONE product lines. Go-to-market is split between prescription pharmaceutical sales via sales representatives to hospitals and clinics, and consumer/cosmeceutical sales via pharmacies, medical aesthetics clinics, and e-commerce. Nephoxil has received regulatory approval in seven major jurisdictions — US (2014), Japan (2014), EU (2015), Taiwan (2015), Korea (2022, partnership terminated February 2024), Thailand (2023), and China (2026) — making it the first Taiwanese-developed chemical NCE to achieve global market launch.

Name

Panion & BF Biotech Inc.

Legal name

寶齡富錦生技股份有限公司

Website

https://pbf.com.tw

Company type

Public

Founded year

1976

Operating status

Operating

Headcount range

251–500 employees

Short description

Panion & BF Biotech Inc. is a Taiwan-based, publicly listed biotech pharmaceutical company (TWSE: 1760) that develops and globally licenses Nephoxil, a ferric citrate kidney disease drug, and manufactures generic pharmaceuticals, rapid diagnostic kits, and cosmeceutical skincare lines for hospitals, clinics, pharmacies, and consumers.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

akta.pro secondary industries

Nephrology & Urology Pharmaceuticals (HLAIAAAM), Dermatology Specialty Pharmaceuticals (HLAIACAL), Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Biopharmaceutical manufacturing
• Prescription kidney drugs
• Medical cosmeceuticals
• Rapid diagnostic tests
• Dermatology skincare products

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Sales of patented new drugs (Nephoxil), generic drugs across multiple therapeutic categories including cardiovascular, cold medications, antibacterial, prostate, pain relief, gastrointestinal, and psychiatric medications. Also includes topical preparations, dermatological products, and gynecological medications.
2. Medical Aesthetics and Cosmeceuticals: Sales of skincare products, anti-aging treatments, BDS product line including 5D hyaluronic acid essence, centella asiatica repair cream, amino acid moisturizing lotion, and The ONE premium salon products.
3. Diagnostic Products: Sales of rapid diagnostic test reagents including H. pylori antigen rapid test, influenza A+B rapid test, and Streptococcus A rapid test.
4. Functional Foods and Health Supplements: Sales of nutritional supplements, healthcare products, and BDSNight magnesium capsules for health maintenance.
5. Licensing Royalties: Revenue from licensing Nephoxil to international partners including Keryx/Akebia (US), JT/Torii (Japan), Kyowa Hakko Kirin (Korea), Averoa (Europe), DKSH (Thailand), and Weigao Group (China).
6. Personal Care and Disinfection Products: Sales of hand disinfectants, skin disinfectants, mouthwash, and BDS 99.9% antibacterial wipes.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Panion & BF Biotech Inc. is a diversified pharmaceutical and biotech manufacturer that develops, produces, and commercializes prescription pharmaceuticals (notably Nephoxil ferric citrate for hyperphosphatemia and iron-deficiency anemia in chronic kidney disease patients), medical aesthetics and cosmeceutical skincare lines (BDS, THE ONE, Germain, Spring, Neo Living), rapid in-vitro diagnostic test kits (Vstrip brand for H. pylori, influenza A+B, Group A Streptococcus), and functional health supplements, supported by proprietary platforms including the Sachitin chitin-polysaccharide active ingredient and BiD250 deep-skin controlled-release technology.

Product overview

Panion & BF Biotech Inc. (寶齡富錦生技, stock code 1760) is a diversified biotech pharmaceutical company founded in 1976, operating as a multi-faceted platform across four core business areas: disease treatment (pharmaceuticals), disease prevention (infection control), disease diagnosis (diagnostic kits), and delay of aging (cosmeceuticals). The company's product portfolio centers on Nephoxil (拿百磷), its flagship kidney disease new drug approved across major global markets including Taiwan, US, EU, Japan, Korea, Thailand, and China. The company leverages proprietary technology platforms including Sachitin (寶齡醣丁體), a 20+ year developed anti-aging active ingredient from Ganoderma lucidum, and BiD250 smart deep skin technology for targeted cosmetic delivery. Key product lines include the BDS medical cosmetics brand, THE ONE cosmeceuticals, Germain premium skincare, Vstrip rapid diagnostic reagents, and a comprehensive portfolio of pharmaceuticals spanning cardiovascular, anti-infective, dermatological, and other therapeutic categories. The company also operates through sub-brands including Spring (青春源) for medical aesthetics, Neo Living for clinical skincare, and RaceOn for sports medicine.

Differentiator

Problem solved

Functional benefit

Brands

• 青春源 (Spring): Professional medical aesthetics products brand
• Vstrip
• RaceOn
• Reverse Age

Products and services

• Nephoxil (拿百磷) Prescription kidney-disease drug (active ingredient: Ferric Citrate) for the treatment of hyperphosphatemia in dialysis patients and iron-deficiency anemia in chronic kidney disease patients. First Taiwanese-developed chemical new drug to achieve global market launch; sold to hospitals, clinics, and licensed pharmacies.
• Vstrip Rapid Diagnostic Test Kits Brand portfolio of rapid in-vitro diagnostic test reagents including H. pylori antigen, A+B type influenza, and Group A Streptococcus rapid tests. Sold to hospitals, clinics, and pharmacies; H. pylori test received US FDA 510(k) clearance.
• BDS (必美適) Medical Beauty Skincare Line Medical-grade skincare and personal-care line including 5D Hyaluronic Acid Essence, centella asiatica repair products, amino acid moisturizing lotion, BDSNight magnesium capsules, and 99.9% antibacterial wipes. Targeted at consumers through pharmacies, medical-aesthetics clinics, and e-commerce.
• THE ONE (活煥) Professional Skincare Professional salon-grade skincare line featuring the Alpine Whitening Series and Snow Fungus Moisturizing Series, formulated with 30 years of dermatology expertise and pharmaceutical-grade standards. Sold through medical-aesthetics clinics and consumer channels.
• Germain Premium Salon Skincare High-end salon skincare brand including Spot Control LIFT, Excellence O2, Q-Vita, Timexpert Radiance C series, and the 4D Water Light Moisturizing Series (essence, nourishing cream, concentrated serum) for premium anti-aging skincare delivered to high-end salons and consumers.
• Spring (青春源) Medical Aesthetics Brand Professional medical-aesthetic skincare brand targeting anti-aging and skin rejuvenation, distributed through aesthetic clinics and dedicated online storefront.
• Neo Living Clinical Skincare Clinical-grade medical beauty skincare line including hydrating cleansing water and other professional beauty products sold through medical aesthetics clinics.
• RaceOn Sports Medicine Brand Sports medicine and athletic healthcare product brand offering performance and recovery products to consumers and athletes.
• Sachitin (寶齡醣丁體) Active Ingredient Proprietary natural active ingredient derived from purified and concentrated Ganoderma lucidum (lingzhi) cell walls; colorless, odorless, water-oil soluble chitin-polysaccharide chelate used as the anti-aging and repair active in PBF's cosmeceutical products.

Quantifiable outcome

• Nephoxil received regulatory approval in USA (2014), Japan (2014), EU (2015), Taiwan (2015), Korea (2022), Thailand (2023), China (2026)
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core.

• 威高腹膜透析科技(威海)有限公司coreChannel Partner/ Reseller/ Distributor · 5 June 2026Exclusive authorization for ferric citrate capsules (Nephoxil) in mainland China. Partner authorized as domestic responsible person and general agent for national medical insurance registration, data submission, price negotiation, regulatory compliance, and market preparation. Authorization period of one year from signing.
• Averoa SAScoreChannel Partner/ Reseller/ Distributor · 30 December 2022European licensing partner. Akebia signed exclusive licensing agreement with Averoa for European Economic Area in December 2022. Averoa obtained EU regulatory approval in June 2025.
• DKSH (Thailand) LimitedcoreChannel Partner/ Reseller/ Distributor · 12 November 2019Exclusive distribution agreement for Nephoxil in Thailand market. DKSH obtained NDA new drug import approval in October 2023.
• 裕利股份有限公司 (Zuellig Pharma)coreChannel Partner/ Reseller/ Distributor · 9 October 2018Exclusive distribution agreement for Nephoxil in Taiwan market. Zuellig Pharma handles local distribution, warehousing, and sales to hospitals and clinics.
• Akebia Therapeutics / Keryx BiopharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 6 September 2014US licensing partner for Nephoxil. Keryx obtained FDA approval in September 2014. Keryx subsequently merged with Akebia in 2018, continuing the partnership.
• 威高集團/山東威高藥業 (Weigao Group)coreStrategic or Co-development Partner · 2 September 2014Strategic partnership for Nephoxil market entry in China. PBF and Weigao planned to establish a joint venture company for China market development. Weigao is one of China's top 10 pharmaceutical companies (ranked 6th).
• Kyowa Hakko Kirin Korea (協和醱酵麒麟)coreChannel Partner/ Reseller/ Distributor · 27 August 2014Korean licensing partner for Nephoxil. Obtained MFDS NDA approval in May 2022. Partnership terminated in February 2024 due to parent's Asia-Pacific business reorganization.
• JT/Torii (Japan Tobacco/Torii Pharmaceutical)coreChannel Partner/ Reseller/ Distributor · 17 January 2014Japan licensing partner for Nephoxil (marketed as Riona in Japan). Successfully obtained Japanese Ministry of Health approval in January 2014.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Akebia Therapeutics: US partner that markets ferric citrate (formerly Auryxia) — acquired Keryx Biopharmaceuticals in 2018 — and is the US licensee for PBF's Nephoxil. Direct comparator because they commercialize the same molecule in North America and share the same regulatory and clinical evidence base.
• Japan Tobacco / Torii Pharmaceutical: Japanese licensee marketing Nephoxil as Riona. Comparable as a regional specialty pharma commercializing a PBF-originated asset in a major Asian market.
• Keryx Biopharmaceuticals: Pre-merger US partner that obtained the original 2014 FDA approval for ferric citrate. Highly comparable as a small US specialty pharma that launched the same asset PBF originated.
• PharmaEngine: Taiwan-listed specialty oncology pharma with similar company profile: Taiwan-domiciled, publicly listed, focused on niche global out-licensing of regionally developed new drugs.
• Weigao Group: Top-10 Chinese medical device/pharma conglomerate and PBF's strategic partner for Nephoxil China. Comparable because it bridges specialty pharma and consumer medical products in the China market and is the immediate counterparty for PBF's largest forward growth opportunity.

Broad incumbents

• Kyowa Kirin: Former Korean licensee for Nephoxil and a broad Japanese-headquartered specialty pharma. Comparable because it operates the same kind of nephrology/specialty therapeutic franchises and is representative of the partner profile PBF depends on.
• DKSH Holding: Thai/Aregional market-expansion services partner and Nephoxil licensee in Thailand. Comparable because it handles regulatory, distribution, and commercialization for Nephoxil and adjacent pharma/consumer health assets across Southeast Asia.
• AmorePacific: Korean beauty/cosmeceutical major. Comparable for the BDS/The ONE/Germain cosmeceutical franchise — both sell premium skincare in Asia with pharma-grade R&D claims and multiple sub-brands.

Emerging players

• Mycenax Biotech: Taiwan-based biologics/formulation specialist. Comparable as a domestic Taiwanese biotech using proprietary delivery and formulation science to develop specialty pharma products.

Regional players

• Center Laboratories: Taiwan-listed specialty pharmaceutical manufacturer with PIC/S GMP capabilities and a diversified generics/specialty portfolio. Comparable in manufacturing footprint, regulatory certifications, and Taiwanese specialty pharma positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/panion-bf-biotech-inc

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Panion & BF Biotech Inc.